Výsledky vyhledávání - "Fadia Qiryaqos"

Abstract 3499: Inhibition of SOS1 by MRTX0902 augments the anti-tumor response of the targeted EGFR inhibitor osimertinib in NSCLC

Autor: Shilpi Khare, Niranjan Sudhakar, Jade Laguer, David M. Briere, Larry Yan, Allan Hebbert, Andrew Calinisan, Lars D. Engstrom, Fadia Qiryaqos, Peter Olson, James G. Christensen, Jacob R. Haling

Publikováno v: Cancer Research. 83:3499-3499

Osimertinib is a third generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor recommended as a first line therapy in patients with advanced non-small lung cancer (NSCLC) characterized by EGFR activating mutations (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5ea99e6ddf20a56522bbb06dad376405
https://doi.org/10.1158/1538-7445.am2023-3499

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání